Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease

Danish Medical Journal

Volumn 60, Issue 4, 2013, Pages

  Steenholdt, Casper ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; HEMOGLOBIN; INFLIXIMAB; ANTIBODY; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CROHN DISEASE; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; LEUKOCYTE COUNT; LIMIT OF DETECTION; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; RADIOIMMUNOASSAY; REPRODUCIBILITY; RISK FACTOR; SPECTROPHOTOMETRY; THROMBOCYTE; TURBIDIMETRY; BLOOD; DRUG RESISTANCE; IMMUNOLOGY; MAINTENANCE CHEMOTHERAPY; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG RESISTANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MAINTENANCE CHEMOTHERAPY; RADIOIMMUNOASSAY;

EID: 84877303100     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (220)

1. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12 Suppl 1:S3-S9.
2. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol 2007; 102(9):2058-2069.
3. Dignass A, Van AG, Lindsay JO, Lemann M, Soderholm J, Colombel JF et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010; 4(1):28-62.
4. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104(2):465-483.
5. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60(5):571-607.
6. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106(2):199-212.
7. Allez M, Karmiris K, Louis E, Van AG, Ben-Horin S, Klein A et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4(4):355-366.
8. Lacana E, Amur S, Mummanneni P, Zhao H, Frueh FW. The emerging role of pharmacogenomics in biologics. Clin Pharmacol Ther 2007; 82(4):466-471.
9. Rutgeerts P, Vermeire S, Van AG. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136(4):1182-1197.
10. U.S.Food and Drug Administration. Prescribing information on Natalizumab. 2011. http://www.fda.gov/
11. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30(16):1443-1453.
12. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109(1):129-135.
13. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337(15):1029-1035.
14. European Medicines Agency (EMA). European Public Assessment Report (EPAR) for Remicade. 2011. http://www.ema.europa.eu/
15. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130(2):323-333.
16. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56(9):1232-1239.
17. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132(1):52-65.
18. European Medicines Agency (EMA). European Public Assessment Report (EPAR) for Humira. 2011. http://www.ema.europa.eu/
19. Perrier C, Rutgeerts P. Cytokine blockade in inflammatory bowel diseases. Immunotherapy 2011; 3(11):1341-1352.
20. Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008; 126(2):121-136.
21. Chowers Y, Sturm A, Sans M, Papadakis K, Gazouli M, Harbord M et al. Report of the ECCO workshop on anti- TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis 2010; 4(4):367-376.
22. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford) 2010; 49(7):1215-1228.
23. Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factoralpha antibodies. Scand J Gastroenterol 2009; 44(7):774-781.
24. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36(1):3-10.
25. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002; 24(11):1720-1740.
26. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol 2007; 28(11):482-490.
27. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007; 46(12):1828-1834.
28. Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60(1):41-48.
29. Bendtzen K. Immunogenicity of anti-TNF Antibodies. In: van de Weert M, Møller EH, editors. Biotechnology: Pharmaceutical Aspects Vol. VIII. Immunogenicity of biopharmaceuticals. Springer; 2008. 189-203.
30. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, Van der Woude J. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008; 28(9):1122-1126.
31. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137(5):1628-1640.
32. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007; 27(3):269-274.
33. Ada GL. The immunological principles of vaccination. Lancet 1990; 335(8688):523-526.
34. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93(11):2645-2668.
35. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007; 46(8):645-660.
36. Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001; 19(12):491-496.
37. Shankar G, Shores E, Wagner C, Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 2006; 24(6):274-280.
38. European Medicines Agency (EMA). Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins. 2007. http://www.ema.europa.eu/
39. European Medicines Agency (EMA). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. 2008. http://www.ema.europa.eu/
40. Van AG, Dignass A, Reinisch W, VAN DER Woude CJ, Sturm A, De VM et al. The second European evidencebased Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis 2010; 4(1):63-101.
41. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and metaanalysis. Am J Gastroenterol 2011; 106(4):644-59.
42. Kamm MA, Ng SC, De CP, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn's disease. Inflamm Bowel Dis 2011; 17(11):2366-2391.
43. Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011; 106 Suppl 1:S2-25.
44. Peyrin-Biroulet L, Lemann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33(8):870-879.
45. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126(2):402-413.
46. Armuzzi A, Van AG, Reinisch W, Pineton de CG, Griffiths A, Sladek M et al. Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. J Crohns Colitis 2012; 6(4):492-502.
47. Daperno M, Castiglione F, de RL, Dotan I, Farkkila M, Florholmen J et al. Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis 2011; 5(5):484-498.
48. Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H et al. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011; 5(5):477-483.
49. Baars JE, Nuij VJ, Oldenburg B, Kuipers EJ, Van der Woude CJ. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis 2011 Nov 8. doi: 10.1002/ibd.21925. [Epub ahead of print]
50. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van AG et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58(4):492-500.
51. Toruner M, Loftus EV, Jr., Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134(4):929-936.
52. Jones JL, Loftus EV, Jr. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis 2007; 13(10):1299-1307.
53. Van AG, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134(7):1861-1868.
54. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362(15):1383-1395.
55. Sokol H, Seksik P, Carrat F, Nion-Larmurier I, Vienne A, Beaugerie L et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59(10):1363-1368.
56. Moss AC, Kim KJ, Fernandez-Becker N, Cury D, Cheifetz AS. Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. Dig Dis Sci 2010; 55(5):1413-1420.
57. Ordas I, Feagan BG, Sandborn WJ. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut 2011; 60(12):1754-1763.
58. D'Haens G, Baert F, Van AG, Caenepeel P, Vergauwe P, Tuynman H et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371(9613):660-667.
59. Krygier DS, Ko HH, Bressler B. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs. Expert Rev Gastroenterol Hepatol 2009; 3(4):407-415.
60. Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142(1):63-70.
61. Waugh AW, Garg S, Matic K, Gramlich L, Wong C, Sadowski DC et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010; 32(9):1129-1134.
62. Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Ostergaard TO, Seidelin JB. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012; 47(5):518-527.
63. Solberg IC, Vatn MH, Hoie O, Stray N, Sauar J, Jahnsen J et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5(12):1430-1438.
64. Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007; 133(1):312-339.
65. Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A et al. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis 2010; 4(3):221-256.
66. Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 2010; 24(2):167-182.
67. Vermeire S, Van AG, Rutgeerts P. Serum sickness, encephalitis and other complications of anti-cytokine therapy. Best Pract Res Clin Gastroenterol 2009; 23(1):101-112.
68. Moss AC, Fernandez-Becker N, Jo KK, Cury D, Cheifetz AS. The impact of infliximab infusion reactions on longterm outcomes in patients with Crohn's disease. Aliment Pharmacol Ther 2008; 28(2):221-227.
69. Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011; 7(1):55-63.
70. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359(9317):1541-1549.
71. Peyrin-Biroulet L, Deltenre P, de SN, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: metaanalysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6(6):644-653.
72. Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70(3):439-444.
73. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122(2):512-530.
74. Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003; 17 Suppl 2:11-17.
75. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011; 106(4):685-698.
76. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104(3):760-767.
77. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33(9):987-995.
78. Louis E, Belaiche J, Reenaers C. Anti-TNF and Crohn's disease: when should we stop? Curr Drug Targets 2010; 11(2):148-151.
79. Danese S, Colombel JF, Reinisch W, Rutgeerts PJ. Review article: infliximab for Crohn's disease treatment-shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 2011; 33(8):857-869.
80. Fallingborg J, Nordgaard-Lassen I, Dahlerup JF, Munck L.K, de Muckadell O.S, Tage-Jensen U et al. Behandlingsvejledning for terapiområdet biologisk behandling af kroniske inflammatoriske tarmsygdomme. 2012. http://www.regioner.dk/
81. Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J et al. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-alpha) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess 2011; 15(6):1-244.
82. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007; 26(11-12):1509-1520.
83. Mulani P, Chao J. Infliximab vs. Adalimumab for Crohn's disease. Aliment Pharmacol Ther 2008; 28(10):1265-1266.
84. Chao J, Mulani P. What is the rate of loss of response to infliximab therapy in Crohn's disease? Am J Gastroenterol 2009; 104(9):2353-2354.
85. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350(9):876-885.
86. Regueiro M, Siemanowski B, Kip KE, Plevy S. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007; 13(9):1093-1099.
87. Kopylov U, Mantzaris GJ, Katsanos KH, Reenaers C, Ellul P, Rahier JF et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 2011; 33(3):349-357.
88. Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt C, Mantzaris GJ et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012 Jan 31. doi: 10.1002/ibd.22902. [Epub ahead of print]
89. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46(6):1451-1459.
90. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146(12):829-838.
91. Ma C, Panaccione R, Heitman SJ, Devlin SM, Ghosh S, Kaplan GG. Systematic review: the short-term and longterm efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther 2009; 30(10):977-986.
92. Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E et al. The efficacy and safety of a third anti TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010; 31(1):92-101.
93. de Silva PS, Nguyen DD, Sauk J, Korzenik J, Yajnik V, Ananthakrishnan AN. Long-term outcome of a third anti- TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36(5):459-466.
94. U.S.Food and Drug Administration. Prescribing information on Certolizumab Pegol. 2011. http://www.fda.gov/
95. Chaparro M, Panes J, Garcia V, Merino O, Nos P, Domenech E et al. Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis 2012; 18(4):685-690.
96. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357(3):239-250.
97. Danese S, Fiorino G, Reinisch W. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNFalpha therapy. Aliment Pharmacol Ther 2011; 34(1):1-10.
98. Van AG, Vermeire S, Rutgeerts P. Management of loss of response to anti-TNF drugs: Change the dose or change the drug? J Crohns Colitis 2008; 2(4):348-351.
99. Vermeire S, Louis E, Carbonez A, Van AG, Noman M, Belaiche J et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97(9):2357-2363.
100. Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123(3):707-713.
101. Lionetti P, Bronzini F, Salvestrini C, Bascietto C, Canani RB, De Angelis GL et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003; 18(4):425-431.
102. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000; 95(11):3189-3194.
103. Mascheretti S, Schreiber S. Genetic testing in Crohn disease: utility in individualizing patient management. Am J Pharmacogenomics 2005; 5(4):213-222.
104. Matsukura H, Ikeda S, Yoshimura N, Takazoe M, Muramatsu M. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease. Aliment Pharmacol Ther 2008; 27(9):765-770.
105. Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004; 20(3):303-310.
106. Beutler B. Autoimmunity and apoptosis: the Crohn's connection. Immunity 2001; 15(1):5-14.
107. Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, van SN et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther 2005; 22(7):613-626.
108. Steenholdt C, Enevold C, Ainsworth MA, Brynskov J, Thomsen OO, Bendtzen K. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease. Aliment Pharmacol Ther 2012 Aug 5. doi: 10.1111/apt.12010. [Epub ahead of print]
109. Arijs I, Quintens R, Van LL, Van SK, De HG, Lemaire K et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm Bowel Dis 2010; 16(12):2090-2098.
110. Arijs I, Li K, Toedter G, Quintens R, Van LL, Van SK et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009; 58(12):1612-1619.
111. Jurgens M, Mahachie John JM, Cleynen I, Schnitzler F, Fidder H, van MW et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011; 9(5):421-427.
112. Reinisch W, Wang Y, Oddens BJ, Link R. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012; 35(5):568-576.
113. Card T. Commentary: is CRP ready for use to indicate response or remission with infliximab in Crohn's? Aliment Pharmacol Ther 2012; 35(8):960-961.
114. Laharie D, Mesli S, El HF, Chabrun E, Chanteloup E, Capdepont M et al. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther 2011; 34(4):462-469.
115. Molander P, Af Bjorkesten CG, Mustonen H, Haapamaki J, Vauhkonen M, Kolho KL et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFalpha blocking agents. Inflamm Bowel Dis 2012 Jan 4. doi: 10.1002/ibd.22863. [Epub ahead of print]
116. Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J et al. Infliximab induces potent antiinflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001; 15(4):463-473.
117. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348(7):601-608.
118. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4(10):1248-1254.
119. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008; 103(4):944-948.
120. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59(1):49-54.
121. Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis 2010; 16(11):1898-1904.
122. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009; 15(8):1264-1275.
123. Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a metaanalysis. Eur J Gastroenterol Hepatol 2012; 24(9):1078-1085.
124. Chaparro M, Guerra I, Munoz-Linares P, Gisbert JP. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012 Mar 22. doi: 10.1111/j.1365-2036.2012.05057.x. [Epub ahead of print]
125. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2(7):542-553.
126. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56(9):1226-1231.
127. Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004; 38(5):502-508.
128. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006; 54(12):3782-3789.
129. van der Laken CJ, Voskuyl AE, Roos JC, Stigter van WM, de Groot ER, Wolbink G et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and nonresponders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007; 66(2):253-256.
130. Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008; 30(4):523-529.
131. Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P, Xu W et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008; 48(6):681-695.
132. Rojas JR, Taylor RP, Cunningham MR, Rutkoski TJ, Vennarini J, Jang H et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 2005; 313(2):578-585.
133. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124(4):917-924.
134. Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cezard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol 2006; 118(1):11-19.
135. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340(18):1398-1405.
136. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23):2462-2476.
137. Pariente B, Pineton de CG, Krzysiek R, Desroches M, Louis G, De CC et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18(7):1199-1206.
138. Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65(5):657-661.
139. Colombel JF, Feagan BG, Sandborn WJ, Van AG, Robinson AM. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012; 18(2):349-358.
140. Bendtzen K, Svenson M. Detection and quantification of antibodies to biopharmaceuticals: Practical and applied. John Wiley & Sons Ltd, West Sussex, UK; 2011.
141. Hennig C, Rink L, Fagin U, Jabs WJ, Kirchner H. The influence of naturally occurring heterophilic antiimmunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods 2000; 235(1-2):71-80.
142. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68(11):1739-1745.
143. Aarden L, Ruuls SR, Wolbink G. Immunogenicity of antitumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008; 20(4):431-435.
144. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009; 21(3):211-215.
145. Munkholm P, Langholz E, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol 1992; 27(7):609-614.
146. Harvey RF, Bradshaw JM. A simple index of Crohn'sdisease activity. Lancet 1980; 1(8167):514.
147. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010; 8(4):357-363.
148. Schoepfer AM, Vavricka S, Zahnd-Straumann N, Straumann A, Beglinger C. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis 2012; 6(4):412-418.
149. Ben-Horin S, Mazor Y, Yanai H, Ron Y, Kopylov U, Yavzori M et al. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther 2012; 35(6):714-722.
150. Colombel JF, Loftus EV, Jr., Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126(1):19-31.
151. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1(8476):307-310.
152. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011; 46(3):310-318.
153. Svenson M, Jacobi HH, Bodtger U, Poulsen LK, Rieneck K, Bendtzen K. Vaccination for birch pollen allergy. Induction of affinity-matured or blocking IgG antibodies does not account for the reduced binding of IgE to Bet v 1. Mol Immunol 2003; 39(10):603-612.
154. Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 2006; 28(2):169-174.
155. Sjobring U, Bjorck L, Kastern W. Streptococcal protein G. Gene structure and protein binding properties. J Biol Chem 1991; 266(1):399-405.
156. Lallemand C, Kavrochorianou N, Steenholdt C, Bendtzen K, Ainsworth MA, Meritet JF et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods 2011; 373(1-2):229-239.
157. Vermeire S, Van AG, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10(5):661-665.
158. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140(6):1817-1826.
159. Vilela EG, Torres HO, Martins FP, Ferrari ML, Andrade MM, Cunha AS. Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis. World J Gastroenterol 2012; 18(9):872-881.
160. Arnese M, Salustri A, Fioretti PM, Cornel JH, Boersma E, Reijs AE et al. Quantitative angiographic measurements of isolated left anterior descending coronary artery stenosis. Correlation with exercise echocardiography and technetium-99m 2-methoxy isobutyl isonitrile single- photon emission computed tomography. J Am Coll Cardiol 1995; 25(7):1486-1491.
161. https://faculty.vassar.edu/lowry/clin1.html
162. Afif W, Loftus EV, Jr., Faubion WA, Kane SV, Bruining DH, Hanson KA et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105(5):1133-1139.
163. Steenholdt C, Svenson M, Bendtzen K, Thomsen OO, Brynskov J, Ainsworth MA. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. J Crohns Colitis 2012; 6(1):108-111.
164. Wagner CL, Schantz A, Barnathan E, Olson A, Mascelli MA, Ford J et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 2003; 112:37-53.
165. Bendtzen K. Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies? Arthritis Rheum 2011; 63(4):867-870.
166. www.medstat.dk
167. Wadhwa M, Bird C, Dilger P, Gaines-Das R, Thorpe R. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J Immunol Methods 2003; 278(1-2):1-17.
168. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004; 289(1-2):1-16.
169. Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 2007; 321(1-2):1-18.
170. Geng D, Shankar G, Schantz A, Rajadhyaksha M, Davis H, Wagner C. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J Pharm Biomed Anal 2005; 39(3-4):364-375.
171. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11(1-2):81-88.
172. Bendtzen K. Anti-IFN BAb and NAb antibodies: a minireview. Neurology 2003; 61(9 Suppl 5):S6-10.
173. Wang S, Ohrmund L, Singh S. Measurement of human anti-chimeric antibodies (Haca) and infliximab levels in paitent serum using a novel homogeneous assay. Gastroenterology 2010; 138(5, suppl.1):S-684.
174. Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 2012; 382(1-2):177-188.
175. Hauenstein S, Ohrmund L, Salbato J, Reddy R, McCowen K, Monk P et al. Comparison of homogeneous mobility shift assay and solid phase ELISA for the measurement of drug and anti-drug antibody (ADA) levels in serum from patients treated with anti-TNF biologics. Gastroenterology 2012; 142(5, suppl.1):S-538.
176. Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate determination of antiinfliximab antibodies in inflammatory bowel disease. J Gastroenterol 2012; 47(2):136-143.
177. Hart MH, de VH, Wouters D, Wolbink GJ, Killestein J, de Groot ER et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011; 372(1-2):196-203.
178. Rispens T, de VH, de GE, Wouters D, Stapel S, Wolbink GJ et al. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J Immunol Methods 2012; 375(1-2):93-99.
179. Bendtzen K, Steenholdt C, Ainsworth M, Thomsen OO, Brynskov J. Comment on 'Predicting the response to in fliximab from trough serum levels'. Gut 2010; 59(9):1298-1299.
180. Aalberse RC, van der Gaag R, van LJ. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 1983; 130(2):722-726.
181. Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology 2002; 105(1):9-19.
182. van der Neut KM, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E et al. Antiinflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317(5844):1554-1557.
183. Steenholdt C, Brynskov J, Thomsen OO, Munck LK, Fallingborg J, Christensen LA et al. Comparison of techniques for monitoring infliximab and antibodies to infliximab in Crohn's disease patients with infliximab treatment failure. Am J Gastroenterol 2012; 107(10);Suppl.1:P-982.
184. Kopylov U, Mazor Y, Yavzori M, Fudim E, Katz L, Coscas D et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 2012; 18(9):1628-1633.
185. Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012; 91(4):635-646.
186. Steenholdt C, Ainsworth M, Thomsen OO, Brynskov J, Bendtzen K. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factoralpha inhibitors]. Ugeskr Laeger 2010; 172(1):44-47.
187. Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64(5):704-707.
188. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011; 33(7):946-964.
189. Takeuchi T, Miyasaka N, Tatsuki Y, Yano T, Yoshinari T, Abe T et al. Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70(7):1208-1215.
190. Nikolaus S, Raedler A, Kuhbacker T, Sfikas N, Folsch UR, Schreiber S. Mechanisms in failure of infliximab for Crohn's disease. Lancet 2000; 356(9240):1475-1479.
191. Bruining DH, Sandborn WJ. Do not assume symptoms indicate failure of anti-tumor necrosis factor therapy in Crohn's disease. Clin Gastroenterol Hepatol 2011; 9(5):395-399.
192. Casteele N, Compernolle G, Ballet V, Van Assche G, Gils A, Vermeire S et al. Results on the optimisation phase of the prospective controlled trough level adapted infliximab treatment (TAXIT) trial. Gastroenterology 2012; 142;Suppl.1:S-114.
193. Vermeire S, Gabriels F, Ballet V, Casteele N, Moerkercke W, Van Assche G et al. The effect of dose escalation on trough levels in patients who loast response to infliximab. Gut 2010; 59;Suppl.1;A-81.
194. Cornillie F, Hanauer S, Diamond RH, Wang J, Zelinger D, Xu Z et al. Can clinical, biological or pharmacological markers predict sustained response to infliximab? A retrospective alanlysis of ACCENT 1. Gut 2011; 60(Suppl.3) A296.
195. Arias MT, Vande CN, Drobne D, Ferrante M, Cleynen I, Ballet V et al. Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis. Journal of Crohn's and Colitis 2012; 6(Suppl.1):S5.
196. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41(9):1552-1563.
197. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de GE, Nurmohamed MT et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54(3):711-715.
198. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69(14):1391-1403.
199. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305(14):1460-1468.
200. Casteele N, Cuypers L, Singh S, Ohrmund L, Hauenstein S, Van Assche G et al. Antibodies to infliximab can either be persistent or transient: A retrospective case-control study in IBD patients treated with infliximab maintenance therapy. Gastroenterology 2012; 142;Suppl.1:OP563.
201. Vande CN, Ballet V, Van AG, Rutgeerts P, Vermeire S, Gils A. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut 2012; 61(2):321.
202. Van AG, Lewis JD, Lichtenstein GR, Loftus EV, Ouyang Q, Panes J et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol 2011; 106(9):1594-1602.
203. Puchner TC, Kugathasan S, Kelly KJ, Binion DG. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001; 7(1):34-37.
204. Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C et al. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther 2006; 24(5):851-858.
205. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358(11):1109-1117.
206. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98(6):1315-1324.
207. Sampson HA, Mendelson L, Rosen JP. Fatal and nearfatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327(6):380-384.
208. Okuyama A, Nagasawa H, Suzuki K, Kameda H, Kondo H, Amano K et al. Fcgamma receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70(2):299-304.
209. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005; 72(4):250-256.
210. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a singlecentre cohort study. Gut 2009; 58(4):501-508.
211. Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002; 97(6):1408-1414.
212. Margo F, Marques M, Santos CC. Episodic infliximab treatment induces infusion reactions. Inflamm Bowel Dis 2008; 14(11):1608-1610.
213. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17(1):75-84.
214. Steenholdt C, Brynskov J, Bendtzen K. Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD. Aliment Pharmacol Ther 2012; 36(5):499-500.
215. Lees CW, Ali AI, Thompson AI, Ho GT, Forsythe RO, Marquez L et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2009; 29(3):286-297.
216. Zabana Y, Domenech E, Manosa M, Garcia-Planella E, Bernal I, Cabre E et al. Infliximab safety profile and longterm applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther 2010; 31(5):553-560.
217. Mantzaris GJ, Viazis N, Petraki K, Papamichael K, Theodoropoulos I, Roussos A et al. A pilot study comparing hydrocortisone premedication to concomitant azathioprine treatment in preventing loss of response to infliximab. Eur J Gastroenterol Hepatol 2009; 21(9):1042-1048.
218. Domenech E, Zabana Y, Manosa M, Garcia-Planella E, Cabre E, Gassull MA. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen. J Clin Gastroenterol 2010; 44(1):34-37.
219. Steenholdt C, Svenson M, Bendtzen K, Thomsen OO, Brynskov J, Ainsworth MA. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay: authors' reply. Aliment Pharmacol Ther 2011; 34(3):404-405.
220. Vande CN, Breynaert C, Vermeire S, Rutgeerts PJ, Gils A, Van AG. Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay. Aliment Pharmacol Ther 2011; 34(3):401-403.